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Abstract: Increasing numbers of beyond Rule-of-Five drugs are emerging from discovery pipelines,
generating a need for bio-enabling formulation approaches, such as lipid-based formulations (LBF),
to ensure maximal in vivo exposure. However, many drug candidates display insufficient lipid
solubility, leading to dose-loading limitations in LBFs. The aim of this study was to explore the potential
of supersaturated LBFs (sLBF) for the beyond Rule-of-Five drug venetoclax. Temperature-induced
sLBFs of venetoclax were obtained in olive oil, Captex® 1000, Peceol® and Capmul MCM®,
respectively. A Peceol®-based sLBF displayed the highest drug loading and was therefore evaluated
further. In vitro lipolysis demonstrated that the Peceol®-based sLBF was able to generate higher
venetoclax concentrations in the aqueous phase compared to a Peceol®-based suspension and an
aqueous suspension. A subsequent bioavailability study in pigs demonstrated for sLBF a 3.8-fold
and 2.1-fold higher bioavailability compared to the drug powder and Peceol®-based suspension,
respectively. In conclusion, sLBF is a promising bio-enabling formulation approach to enhance in vivo
exposure of beyond Rule-of-Five drugs, such as venetoclax. The in vitro lipolysis results correctly
predicted a higher exposure of the sLBF in vivo. The findings of this study are of particular relevance
to pre-clinical drug development, where maximum exposure is required.
Keywords: lipid-based formulation; venetoclax; Super-SNEDDS; supersaturation; amorphous
solubility; landrace pigs; supersaturated lipid-based formulations; lipid suspensions; self-emulsifying
drug delivery system; SEDDS
1. Introduction
In recent decades, it is well recognised that the oral bioavailability of drug candidates is
negatively influenced by trends in drug discovery for candidates with increasing molecular size,
lipophilicity and hydrophobicity [1–3]. In addition, increasingly new drug candidates fall outside the
classical Rule-of-Five drug discovery space, resulting in solubility and/or permeability challenges [2,3].
Such beyond Rule-of-Five drugs necessitate a bio-enabling formulation approach addressing both
solubility and permeability limitations simultaneously. One formulation approach addressing both
limitations is a lipid-based formulation (LBF). LBFs may improve oral bioavailability via a number of
mechanisms including avoidance of a drug dissolution step, an increased extent of drug solubilisation
in intestinal fluids, lipid excipient-mediated increased intestinal permeability as well as possible
enhancement of lymphatic uptake from the gastrointestinal tract [4,5]. However, the LBF development
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is complicated by the fact that for many beyond Rule-of-Five drug substances, it is not possible to
solubilise the dose in a relevant amount of lipid vehicle due to an inherent low drug solubility in
lipid vehicles. For such challenging drug candidates, displaying both poor water and lipid solubility,
advanced formulation strategies that increase drug loading in lipid vehicles, such as lipophilic salts/ionic
liquids [6–10] or supersaturated LBFs (sLBF) [11–13], have recently been proposed.
sLBFs are lipid-based solutions that contain a drug concentration above the thermodynamic
solubility of the drug in the lipid vehicle. Such supersaturated formulations are commonly prepared
using heat [11–13]. While supersaturated formulations may display kinetic stability, thermodynamics
dictate that precipitation will eventually occur depending on the drug properties, lipid vehicle,
supersaturation ratio and storage conditions. sLBFs offer significant advantages in a pre-clinical drug
product development setting, offering a balance between the potential to maximise oral exposure and
facilitating ease of preparation and administration in pre-clinical models, which is particularly relevant
in early toxicological drug evaluations [14]. In the literature, sLBFs of small and highly lipophilic
drugs such as halofantrine [12], simvastatin [11], fenofibrate [15], cinnarizine [16] and R3040 [17] have
been reported. In most cases, a higher oral bioavailability was observed in comparison to either an
aqueous suspension, commercial product or an undersaturated lipid solution. While sLBFs have been
successfully used for small molecules that are highly lipophilic and show low–moderate hydrophobicity,
it remains unclear whether the formulation concept is also applicable to larger-molecular-weight (e.g.,
>500 g/mol) and/or moderate–high hydrophobic drug candidates.
Venetoclax (Figure 1), a selective B-cell lymphoma-2 inhibitor licenced in 2016 for the treatment of
leukaemia, displays a high lipophilicity (logP 5.5), high molecular weight (868.44 g/mol) [18] and a
mid-range melting point (138 ◦C onset) [19]. It is classified as a BCS class IV [20] drug and exhibits
a solubility in aqueous buffer of < 0.0042 µg/mL at pH 7.4 [18]. The commercialised formulation,
Venclyxto®, exhibits a substantial food-dependent bioavailability with a 3.4-fold increase in oral
bioavailability after a low-fat meal and a 5-fold increase after a high fat meal compared to the fasted
state [18]. Venclyxto® is considered to be a solid dispersion in copovidone [19] and must be taken with
food to achieve an adequate bioavailability [19] suggesting that dietary lipids may be beneficial for
improving oral absorption of venetoclax. Venetoclax was chosen as a model drug for the present study
in order to explore whether it can be supersaturated in a lipid vehicle and whether a sLBF improves
in vivo bioavailability using landrace pigs as animal model.
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2. Materials and Methods
Materials. Two venetoclax batches were purchased from Kemprotec Ltd. (UK) (batch 1: #1705150,
batch 2: #180620). One further venetoclax batch was ordered from Sigma-Aldrich (Ireland) (batch
3: #11777). Olive oil, highly refined and low acidity, capric acid, L-α-phosphatidylcholine type XI-E
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(PC) (768 g/mol), taurodeoxycholic acid (NaTDC) and pancreatic lipase (8 × USP) were ordered
from Sigma-Aldrich (Ireland). Capmul MCM® and Captex® 1000 were kindly donated by Abitec
corporation. A sample of Peceol® was kindly provided by Gattefossé (France) and SIF powder version
1 was kindly donated by biorelevant.com (UK). All other chemicals and solvents were of analytical or
high-performance liquid chromatography (HPLC) grade and were purchased from Sigma-Aldrich
(Ireland) and used as received.
Differential scanning calorimetry (DSC). The thermal behaviour of venetoclax was studied using
a TA Q1000 with a TA Refrigerated Cooling System 90 (TA Instruments, New Castle, DE, USA). The cell
was purged with nitrogen at 50 mL/min. The melting temperature was measured by modulated
DSC. Venetoclax (5 mg) was weighed into a T-zero pan and heated from 20 to 200 ◦C at 3 ◦C/min.
The modulation amplitude was set to ± 1.0 ◦C and the modulation time to 60 sec.
The crystallisation behaviour of venetoclax was studied using the protocol by Baird et al. [21].
In brief, 2 mg venetoclax was weighed into a T-zero pan and heated to 165 ◦C at 10 ◦C/min,
held isothermally for 3 min, cooled to −75 ◦C at 20 ◦C/min and reheated to 160 ◦C at 10 ◦C/min. As no
crystallisation was observed during cooling and reheating, the heating rate was lowered to 2 ◦C/min.
The experiments were run in triplicates. The glass-forming ability of drugs was categorised according
to Baird et al. into class I (crystallisation during cooling prior to the glass transition temperature (Tg)),
class II (no crystallisation during cooling, but crystallisation was observed upon reheating above Tg) and
class III (no crystallisation observed during cooling nor reheating to its melting point) [21]. Additionally,
the absence of crystals after heating and upon cooling was confirmed by hot-stage microscopy.
Hot-stage microscopy. Samples were placed in a glass crucible onto a Linkam THMS 600 hot
stage connected to a TP94 temperature controller (Linkam Scientific Instruments, Tadworth, UK).
Samples were heated to 165 ◦C at 10 ◦C/min, held isothermally for 3 min, cooled to 25 ◦C at 20 ◦C/min
and continuously monitored using an Olympus BX51 with an Olympus SC100 camera operated
by Olympus Stream essentials 2.3.3. Images were collected at 40× magnification and the light was
polarised using the polariser U-POT and analysed with the analyser U-ANT. The absence of crystals
was assumed, if no birefringence was observed. The images are presented in the Supplementary
Information (Figure S2).
Cross-polarised light microscopy. The absence of crystals in the supersaturated solution was
confirmed by means of cross-polarised light microscopy using an Olympus BX51 with an Olympus
SC100 camera operated by Olympus Stream essentials 2.3.3. The light was polarised using the polariser
U-POT and analysed with the analyser U-ANT. The absence of crystals was assumed, if no birefringence
was observed.
Solubility studies. The solubility was determined in olive oil, Captex® 1000, Peceol® and
Capmul MCM®. Excess of venetoclax was added to 2 mL of the excipients and stirred at 200 rpm (25%
power) (MIXdrive 15 HT, 2Mag AG, Germany) at 37 ◦C. Samples were taken after 24, 48, and 72 h.
In the case of Peceol® and Capmul MCM®, a high amount of venetoclax dissolved instantly upon
addition to the excipient (exceeding the thermodynamic solubility), which lead to precipitation after
24–48 h. Therefore, Peceol® and Capmul MCM® samples were left at 37 ◦C up to 48 h before the first
sample was taken. All samples were centrifuged at 21,380× g (Mikro 200 R, Hettich GmbH, Germany)
and 37 ◦C for 15 min. The supernatant was transferred to a new sample tube and centrifuged again
under identical conditions. To solubilise the oily excipient, the supernatant was diluted in acetonitrile,
ethyl acetate (1:3, v/v), followed by further 1:10 (v/v) dilution with acetonitrile:ethyl acetate (3:1, v/v).
The obtained samples were diluted appropriately with mobile phase before analysis by reverse phase
HPLC as described below. All samples were run in triplicates.
Biorelevant solubility. Fasted state-simulated intestinal fluid (FaSSIF) and fed state-simulated
intestinal fluid (FeSSIF) were prepared according to the instructions by biorelevant.com. Solutions of
FeSSIF were prepared and used directly, whereas FaSSIF was left at room temperature for 2 h prior to
usage. Excess of venetoclax was added to 2 mL FaSSIF and FeSSIF, respectively. The suspensions were
placed in a water bath shaker with 200 shakes/min at 37 ◦C (GLS400, Grant Instruments, UK). Samples
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were taken at 3, 6 and 24 h and centrifuged at 21,380× g (Mikro 200 R, Hettich GmbH, Germany) for
15 min at 37 ◦C. The supernatant was transferred to a new sample tube and centrifuged again under
identical conditions. Samples were diluted 1:10 (v/v) with mobile phase before analysis.
The samples were analysed using an Agilent 1200 series HPLC system (Agilent Technology Inc.,
Santa Clara, CA, US) that comprised a binary pump, degasser, column oven, autosampler and variable
wavelength detector. Data analysis was performed with EZChrom Elite® version 3.2. Venetoclax was
separated from the sample matrix with a Zorbax® Eclipse Plus-C18 column (5 µm, 4.6 mm × 150 mm)
including a Zorbax® Eclipse Plus-C18 guard column (5 µm, 4.6 mm × 12.5 mm) at 40 ◦C. The mobile
phase consisted of (a) acetonitrile with 0.5% (v/v) trifluoroacetic acid (TFA) and (b) water with 0.5%
(v/v) TFA at a ratio of 53:47 (a:b, v/v) and was used at a flow rate of 1 mL/min. The injection volume
was 20 µL and the detection wavelength was set to 316 nm. The limit of detection (LOD) was 20 ng/mL
and the limit of quantification (LOQ) was 65 ng/mL, determined using the standard error of y-intercept
according to the International Council for Harmonisation (ICH) Q2 guideline [22].
In vitro lipolysis: drug solubilisation during formulation dispersion and digestion. In vitro
lipolysis was performed using a pH-stat apparatus (Metrohm AG, Herisau, Switzerland), comprising
a Titrando® 907 stirrer, 804 Ti-stand, a pH electrode (Metrohm AG, Herisau, Switzerland) and two
800 Dosino® dosing units coupled to a 20 mL automatic burette. The system was operated by the
Tiamo® 2.2 software. The in vitro protocol was amended from Williams et al. [23,24] as reported
previously [25]. In brief, the buffer contained 2 mM TRIS maleate, 150 mM NaCl, and 1.4 mM CaCl2
2H2O, adjusted to pH 6.5. For the digestion experiments, the buffer was supplemented with 3 mM
NaTDC and 0.75 mM PC (digestion buffer) and stirred for 12 h before further usage. The pancreatin
extract was prepared freshly by adding 5 mL of 5 ◦C digestion buffer to 1 g of porcine pancreatic
enzymes (8x USP), which was vortexed thoroughly. The mixture was centrifuged for 15 min at 5 ◦C,
2800× g (Rotina 380 R, Hettich GmbH, Germany) and 4 mL of supernatant was recovered and stored
on ice before further usage.
For the in vitro lipolysis experiment 1.583 g of lipid formulation was dispersed into 57 mL of
digestion buffer for 10 min. Three 1 mL samples were taken at 2.5, 5 and 10 min from the middle of
the vessel. pH of the media was adjusted and maintained at 6.5 using 0.2 M NaOH. To the remaining
54 mL (1.5 g lipid formulation) dispersion 6 mL of pancreatin extract was added to initialise digestion.
After 60 min the released non-ionised free fatty acids (FFAs) were determined by a pH increase in
the buffer to pH 9. An additional blank titration using the digestion buffer was performed and the
released mmol of FFAs from the blank was subtracted from the mmol of FFAs released from the
surfactant formulations
Samples of 4.9 mL were taken at 5, 10, 15, 30, 45 and 60 min during the digestion experiment from
the middle of the vessel. In each sample and after 60 min the enzymes were inhibited by the addition
of 1 M 4- Bromophenylboronic acid in methanol (5 µL per mL sample). All samples containing a
lipid phase were centrifuged at 37 ◦C and 400,000× g for 30 min (Beckman Coulter Optima L-90K,
Rotor: VTI 65.2). Samples, that did not contain a lipid phase (aqueous suspension) were centrifuged at
37 ◦C and 21,000× g for 30 min using a benchtop centrifuge (Micro 200 R, Hettich GmbH, Germany).
The lipid phase was dissolved in a mixture of ethyl acetate and acetonitrile (3:1 v/v) and diluted with
1:10 (v/v) with a mixture of ethyl acetate and acetonitrile (1:3 v/v). The solid phase was added to 2 mL
of a mixture of ethyl acetate and acetonitrile (3:7 v/v) and ultrasonicated for 10 min. The aqueous phase
was diluted 1:10 (v/v) with mobile phase. The resulting lipid, solid and aqueous phase samples were
subsequently centrifuged at 37 ◦C and 21,000× g for 30 min. The resulting supernatants were diluted
further with mobile phase and analysed by HPLC as stated above.
The digestibility of Peceol® was calculated as previously described [26] using the theoretical
released FFAs per g of Peceol® utilising the saponification value (166 mg) on the certificate of analysis:
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where theoretical FFAs are the maximal amount of FFAs that can theoretically be released from Peceol®
in mmol per g of excipient, SV the saponification value in mg KOH per g of excipient and 56.1056 g/mol
the molecular weight of KOH. The maximal absolute amount of theoretically released FFAs can be
calculated by multiplying by the amount of excipient used (i.e., 1.5 g in this study). The % digested can





where the released FFAs provide the total amount that is released at the end of the digestion experiment
including the non-ionised FFAs determined by raising the pH to 9.0 and the theoretical FFAs were
calculated using Equation (1).
Formulation development of supersaturated LBFs. The increase in venetoclax concentration
above its solubility in the excipients was achieved by incorporating venetoclax at an elevated
temperature, i.e., the formulations were heated, kept at elevated (isothermal) temperature and cooled
to room temperature. In detail, excess venetoclax was added to Peceol®, olive oil, Capmul MCM®,
Capex® 1000, respectively, and suspended at 600 rpm (Stuart CD 162 heat-stir, Cole-Parmer, UK).
The vial was sealed with parafilm and a continuous nitrogen stream was purged through the vial
to prevent any oxidation during the heating and cooling process. While continuously stirring at
600 rpm, the suspensions were heated to 70 ◦C and kept at 70 ◦C for 10 min (Stuart CD 162 heat-stir,
Cole-Parmer, UK) followed by cooling to 23 ± 2 ◦C by elevating the vial from the hot plate. Once
the mixtures reached a temperature below 25 ◦C, a 0.5 mL sample was taken, and the remaining
mixture was heated and cooled again using the same protocol described above. After this second
cycle, a second 0.5 mL sample was taken, and the mixture was heated and cooled a third time using
the same conditions as described above followed by a final 0.5 mL sample. During all heating and
cooling cycles, excess venetoclax was present to investigate the maximum achievable concentration
with this protocol. The samples were centrifuged at 21,380× g and 37 ◦C (Mikro 200 R, Hettich GmbH,
Germany) for 15 min. The supernatant was transferred to a new sample tube and centrifuged again
using identical conditions. The supernatant was used for HPLC analysis using the same dilutions and
solvents as described for the solubility studies in the lipid excipients above. The remaining suspension
after the third heating cycle was centrifuged under identical conditions as stated above and transferred
to a new sample tube for stability testing and stored at room temperature. The stability of promising
formulations was evaluated using polarised light (Allen Viewer Type LV28, P.W. Allen & Co Ltd.,
Tewkesbury, UK). Due to the high drug amount needed, these formulations and stability tests were
conducted once.
Formulations for in vivo and in vitro studies. For the in vivo used powder venetoclax
formulation, 100 mg venetoclax were weighed into hard gelatine capsules of size 00. For the
in vivo used Peceol® suspension, 50 mg venetoclax was weight into hard gelatine capsules of size 000
and 1 mL of Peceol® (melted at 50 ◦C and cooled to 37 ◦C) was added. Venetoclax was dispersed by
vigorous shaking.
In the in vitro experiments, the powder formulation was resembled by an aqueous suspension.
The aqueous suspension was prepared by adding 50 mg venetoclax to 1 mL water followed by
ultrasonication. The suspensions were stirred constantly to prevent sedimentation before usage. The
Peceol® suspension was prepared by melting Peceol® at 50 ◦C and cooling it to 37 ◦C before adding
50 mg venetoclax to 1 mL Peceol® followed by an over-night stir.
The supersaturated lipid solution was prepared by adding 300 mg venetoclax to 6 mL Peceol®
(50 mg/mL). The mixture was stirred at 600 rpm (Stuart CD 162 heat-stir, Cole-Parmer, UK) and
sealed with parafilm. A continuous nitrogen stream into the vial removed oxygen throughout the
manufacturing process. After suspending the drug particles, the obtained suspension was slowly
heated to 70 ◦C (Stuart CD 162 heat-stir, Cole-Parmer, UK). The mixture was kept at 70 ◦C for 10 min
and cooled to 25 ◦C while continuously stirring at 600 rpm. Subsequently, the mixture was heated a
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second time under the same conditions as stated above and cooled to room temperature. The absence
of crystals was confirmed using cross-polarised light microscopy. For the in vivo study, sLBF was
administered in hard gelatine capsules of size 000 (1 mL per capsule).
In vivo study. All experiments were approved and conducted with licences issued by the Health
Product Regulatory Authority, Ireland (project licence AE19130/P058) as directed by the EU Statutory
instruments of the EU directive 2010/63/EU (Protection of Animals used for Scientific Purposes). Local
ethical approval was granted by University College Cork Animal Experimentation Ethics Committee
(AEEC). A randomised, three-way cross-over study in 3 male landrace pigs (15–17 kg) was conducted
and each pig received a single dose of 100 mg venetoclax. Pigs were fed approximately 175 g of
standard weanling pig pellet feed twice daily. In the fasted study legs, the final feed of 175 g was
given 24 h prior to dosing. As part of the study design, any remaining food was removed 16 h before
dosing. However, no food remained at this point in any of the groups. On day 1 of the experiment,
an intravenous catheter was inserted from the ear vein into the jugular vein under general anaesthesia,
which was used for blood sampling throughout the study. On day 3, following an overnight fast of
16 h, pigs were administered either a reference capsule with venetoclax powder or two capsules of
either venetoclax Peceol® suspension or a venetoclax supersaturated lipid solution (sLBF) with the aid
of a dosing gun followed by 50 mL of water via a syringe. In order to control the water intake with the
dosage forms, the water availability was restricted for 3 h post-dosing. At all other times, water was
available ad libitum. To facilitate handling during the oral administration, an intramuscular dose of
ketamine (5 mg/kg) and xylazine (1 mg/kg) was administered in both studies. Blood samples were
collected after 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 24 h in heparinised tubes. Upon collection, blood
samples were immediately centrifuged at 3000× g, 4 ◦C for 5.5 min (Eppendorf 5702 R, Rotor A-4-38,
Eppendorf Ltd., Stevenage, UK). The supernatant plasma was harvested and stored at −20 ◦C until
further analysis. A 6 day washout period was maintained between the study legs. Due to a rupture
and spillage of one sLBF capsule during oral dosing to one of the pigs, this experimental unit was
excluded, resulting in n = 2 for the sLBF study group.
Bioanalysis. The plasma concentrations of venetoclax were determined by reversed phase HPLC.
The Agilent 1260 series HPLC system (Agilent Technology Inc., Santa Clara, CA, US) comprised a
binary pump, degasser, temperature controlled autosampler, column oven and diode array detector.
The system was operated, and the data analysed with EZChrom Elite® version 3.3.2. A Zorbax®
Eclipse Plus-C18 column (5 µm, 4.6 mm × 150 mm) with a Zorbax® Eclipse Plus-C18 guard column
(5 µm, 4.6 mm × 12.5 mm) was used for the separation of venetoclax. The mobile phase consisted
of water and acetonitrile with 0.5% (v/v) TFA at a ratio of 47:53 (v/v) and was used at a flow rate of
1.0 mL/min. The sample and column temperature were set at 5 ◦C and 40 ◦C, respectively, and the
detection wavelength was set to 250, 290 and 316 nm. Venetoclax was extracted from the plasma
samples by liquid-liquid extraction. To 500 µL of pig plasma, 50 µL vemurafenib (internal standard
dissolved in acetonitrile) and 450 µL acetonitrile was added. The mixture was mixed thoroughly,
and 1 mL of ethyl acetate was added followed by mixing for 15 s. The mixture was centrifuged at 25 ◦C,
11,500× g for 5 min (Mikro 200 R, Andreas Hettich GmbH & Co. KG, Germany). The supernatant
(1.5 mL) was recovered and transferred to a new sample tube. Subsequently, the supernatant was
dried at 60 ◦C under a nitrogen stream. To the remaining plasma sample, 1 mL of ethyl acetate was
added and the mixture was thoroughly mixed and centrifuged using the same condition as above.
The supernatant was recovered and transferred to the same sample tube that contained the supernatant
of the plasma sample after the first centrifugation (which was dried as described above). After drying
of the supernatant, the residues were reconstituted in 100 µL mobile phase (excluding TFA), followed
by centrifugation at 25 ◦C, 11,500× g for 5 min (Mikro 200 R, Andreas Hettich GmbH & Co. KG,
Germany). The injection volume used for HPLC analysis of the supernatant was 50 µL. The LOD and
LOQ in plasma by this method were 6 and 20 ng/mL, respectively, determined using the standard error
of y-intercept according to ICH Q2 guideline [22]. Linearity was confirmed between 25 and 2.5 µg/mL.
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Data analysis. A one-way analysis of variance (one-way ANOVA) was performed for the lipolysis
data using Tukey’s post-hoc test to compare the different formulation performances and Bartlett’s
test to check for equal variance. The pharmacokinetic parameters were calculated using Gastro Plus®
version 9.5 (Simulations Plus Inc., Lancaster, CA, US) and in-house intravenous data. The plasma
concentration profiles were analysed by non-compartmental analysis.
The statistical analysis for all in vivo parameters was performed using a one-way ANOVA after
using Bartlett’s test to check for equal variance. The pairwise comparison of the groups was based
on Tukey’s multiple range test. All statistical analyses were calculated using GraphPad Prism® 5
(GraphPad Software Inc., San Diego, CA, US).
3. Results
3.1. Biorelevant Solubility
Venetoclax is a structural bulky and high-molecular-weight drug, displaying a mid-range melting
point and high logP (Table 1, Figure 1, Figure S1). Initially, three separate batches of the drug substance
were sourced in order to assess the inter-batch variability of in vitro characteristics. Venetoclax solubility
for each batch was measured in FaSSIF and FeSSIF at 37 ◦C. The results are presented in Table 2.
Table 1. Physicochemical properties and in vivo data of venetoclax.
Physicochemical Characteristics
LogP 1 5.5
Molecular weight [g/mol] 1 868.44
BCS class 2 IV
Food effect 1
3.4-fold cmax and AUC increase with a light meal
5-fold cmax and AUC increase with a high fat meal
Melting point [◦C] 138.61 ± 0.12
◦C 3
138 ◦C onset 4
Glass-forming ability 3 III




Anhydrous calcium hydrogen phosphate
Sodium stearyl fumarate
1 Obtained from FDA Venclexta® (venetoclax) clinical pharmacology and biopharmaceutics review [18]; 2 obtained
from Emami Riedmaier et al. [20]; 3 experimentally determined by DSC for venetoclax batch 1 (Figure S1, Figure 2,
Figure S2); 4 obtained from EMA, CHMP assessment report, Procedure No. EMEA/H/C/004106/000 [19]; 5 obtained
from Section 6.1 of the summary of product characteristics of Venclyxto® as of 09/2018.
The solubility values in FaSSIF were similar for all studied batches, with approximately 1.4–1.7%
drug dissolved of a 100 mg dose in 250 mL of gastrointestinal fluid. In the fed-state media, the solubility
increased 4.8-fold to approximately 6.6–7.7% of a 100 mg dose in 250 mL of gastrointestinal fluid, which
was in line with the in vivo food effect reported for venetoclax (Table 1). In contrast to the atypical
solubility behaviour of venetoclax in lipid vehicles (i.e., high inter-batch variability and oversaturation),
venetoclax solubility in biorelevant media was similar between the three batches. This most likely
reflects the ability to more quickly achieve equilibrium solubility in aqueous buffers due to a lower
viscosity, higher wettability and the presence of bile salts/phospholipids to aid solubilisation.
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Table 2. Biorelevant solubility of venetoclax at 37 ◦C (mean ± SD; n = 3).
Biorelevant Solubility [µg/mL]
Media Batch 1 Batch 2 Batch 3
FaSSIF 5.5 ± 1.0 5.2 ± 0.8 4.8 ± 0.6
FeSSIF 26.3 ± 1.8 30.7 ± 4.0 28.2 ± 0.7
3.2. Solubility in Lipid Excipients
In addition to biorelevant solubility, the solubilities of the three venetoclax batches were determined
in olive oil, Captex® 1000, Peceol® and Capmul MCM®, respectively, at 37 ◦C. Venetoclax solubility in
lipid excipients is shown in Table 3.
Table 3. Apparent solubility of venetoclax in lipid excipients at 37 ◦C (mean ± SD; n = 3).
Solubility in Lipid Excipients [mg/mL]
Excipient Batch 1 Batch 2 Batch 3
Olive oil 2.5 ± 0.2 0.3 ± 0.1 0.4 ± 0.1
Peceol® 19.4 ± 2.0 2.9 ± 0.2 4.3 ± 0.5
Captex® 1000 0.4 ± 0.1 0.7 ± 0.1 1.0 ± 0.2
Capmul MCM® 6.1 ± 0.4 3.7 ± 0.5 5.9 ± 0.4
Variability in venetoclax solubility in the lipid vehicles between the three tested venetoclax
batches was observed. The solubility of different batches of venetoclax in Peceol® varied 6.7-fold
from 2.9 ± 0.2 mg/mL to 19.4 ± 2.0 mg/mL. For olive oil, a variation of 9.2-fold, for Capmul MCM® a
1.6-fold variation and for Captex® 1000 a 2.3-fold variation was observed across the different venetoclax
batches. While two venetoclax batches showed a comparable solubility within an approximately 2-fold
difference (batch 2 and 3), batch 1 was considerably different in the case of both long chain excipients
Peceol® and olive oil. Despite the variability, the solubility screening in pure lipid excipient indicated
that venetoclax showed a higher solubility in monoglycerides than triglycerides. Additionally, a dose
loading comparable to the marketed product of 100 mg/tablet was not reached in any of the studied
excipients precluding the use of a classical lipid solution approach, i.e., not a supersaturated and
hence stable system, for venetoclax in these lipid vehicles. It became apparent during solubility
screening of venetoclax in monoglyceride vehicles (i.e., Peceol® and Capmul MCM®) at 37 ◦C, that the
drug appeared to spontaneously oversaturate following addition of excess drug to the lipid, which
visually appeared to dissolve. However, over time, venetoclax precipitated and thermodynamic
equilibrium was achieved. This phenomenon was also demonstrated quantitatively, where higher
drug concentrations were observed in the first 24–48 h, compared to concentrations at later time points.
In both the monoglyceride vehicles, this oversaturated state was stable for up to 48 h. Such atypical
behaviour of venetoclax displayed challenges for the methodology of determining the thermodynamic
solubility of venetoclax in the lipid vehicles. In fact, while drug solubility at 37 ◦C was monitored
for up to 72 h post-precipitation, the solubility determined in the lipid excipients may not reflect
true ‘thermodynamic’ equilibrium, but rather a higher energy intermediate state. As a result of
this behaviour, where excess drug appeared to dissolve initially and precipitated over 12–48 h in
the solubility studies presented in Table 3, the first concentrations were only determined (i.e., first
sampling point t = 24 h) after the drug had precipitated from an oversaturated system. It is likely
that thermodynamic equilibrium would be achieved over an extended storage period (i.e., weeks).
However, in this study with a 72 h study period, equilibrium solubility may not have been achieved,
hence apparent solubilities are reported. The thermodynamic equilibrium may have been further
influence by the viscosity of the lipid excipients and the glass-forming ability of venetoclax (class III,
Table 1, Figure 2). Nevertheless, this venetoclax-specific effect indicated that monoglycerides may be a
good solubilising vehicle to promote and maintain drug supersaturation.
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3.3. Thermal Properties of Venetoclax
In order to further investigate the atypical behaviour of venetoclax, the thermal behaviour of the
different batches was studied. The results are presented in Table 4 and Figure S1 and showed that
venetoclax batch 1 had a melting point of 138.6 ± 0.1 ◦C, which was similar to the reported onset of the
melting point of 138 ◦C (Table 1) [19], an enthalpy of fusion of 19.9 ± 0.7 kJ/mol and entropy of fusion
of 4.8 ± 0.2 × 10−2 kJ/mol/K. Batch 2 showed similar results, with a melting point of 140.2 ± 0.1 ◦C,
entropy of fusion of 18.4 ± 0.4 kJ/mol and an entropy of fusion of 4.5 ± 0.1 × 10−2 kJ/mol/K. However,
batch 3 showed two endothermal events, with one major peak and one minor peak, indicating that
several crystalline structures could be present. While the major peak showed a similar melting point
compared to the other batches, the entropy and enthalpy of fusion was different when compared to
batch 1 and 2. While batch 3 showed a distinct different thermal behaviour compared to batch 1 and 2,
the solubility of batch 3 was similar to the solubility of batch 2 and different to batch 1.
Table 4. Thermal properties of venetoclax. Enthalpy of fusion (∆Hfus), melting point (Tm) and entropy
of fusion (∆Sfus).
Batch ∆Hfus (kJ/mol) Tm (◦C) ∆Sfus × 10−2 (kJ/mol/K)
1705150 19.9 ± 0.7 138.6 ± 0.1 4.8 ± 0.2
180620 18.4 ± 0.4 140.2 ± 0.1 4.5 ± 0.1
11777 main peak 9.0 ± 1.7 143.2 ± 0.2 2.2 ± 0.4
11777 minor peak 2.7 ± 1.1 129.1 ± 0.2 0.7 ± 0.3
In addition, the glass-forming ability of venetoclax batch 1 was determined by DSC. The results
are presented in Figure 2 and Table 1. The first heating cycle confirmed the melting point of venetoclax
batch 1 as described above. In the second cycle, the venetoclax melt was cooled at a rate of 20 ◦C/min
in order to generate amorphous venetoclax. No crystallisation event was observed during cooling.
Hot-stage cross-polarised microscopy confirmed the generation of amorphous venetoclax and revealed
no crystallisation during cooling to room temperature (25 ◦C) (Figure S2). In the reheating cycle,
no endothermic peak was present showing that venetoclax did not tend to recrystallise, categorising
venetoclax as a class III glass former according to Baird and co-workers definition [21].
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3.4. Supersaturation of Venetoclax in Lipid Excipients
Applying a temperature-induced supersaturation approach, suspensions of venetoclax in lipid
excipients were heated to 70 ◦C, kept at 70 ◦C for 10 min followed by cooling to 25 ◦C. This protocol
was repeated up to three times. An excess of drug (i.e., a solid phase) was present at all times during
heating and cooling. The incorporated concentration of venetoclax, i.e., kinetic solubility, was measured
after cooling in olive oil, Captex® 1000, Peceol® and Capmul MCM®, respectively. At the end of
the experiment, the samples were centrifuged, and the supernatants of promising formulations were
stored at room temperature to evaluate the stability of the supersaturated solutions. Due to the large
quantities of venetoclax required in this screening study, an n = 1 was used at each sampling timepoint.
The venetoclax concentration for all three batches in Peceol®, Capmul MCM®, olive oil and Captex®
1000 is shown in Figure 3. The fold difference between the solubility at 37 ◦C and the maximum
achieved concentration at 70 ◦C is shown in Table 5.
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Table 5. Fold difference between the supersaturated venetoclax concentrations reached at 70 ◦C and
the measured solubility for olive oil, Peceol®, Captex® 1000 and Capmul MCM®, where n = 1 for
initial screening.
Fold Difference
Excipient Batch 1 Batch 2 Batch 3
Olive oil 1.3 18.6 12.5
Peceol® 3.5 67.9 12.1
Captex® 1000 10.1 28.2 3.7
Capmul MCM® 22.3 10.6 5.9
In all excipients, relatively higher concentrations were reached after the heating cycles compared
to the solubility at 37 ◦C. While in the case of olive oil and Captex® 1000 the concentration increases
were high, ranging from 1.3- to 12.5-fold for olive oil and 3.7- to 28.2-fold in the case of Captex® 1000,
the total dissolved amount was in most cases below 5 mg/mL, which is insufficient relative to the clinical
dose and precludes the use of triglycerides for the sLBF approach. For Capmul MCM®, venetoclax
concentrations increased between 5.9- and 22.3-fold. However, only batch 1 was able to generate
venetoclax concentrations above 50 mg/mL. Additionally, Capmul MCM® showed a poor stability
of <1 day, limiting the use of this sLBF to possible ad hoc preparation in pre-clinical development.
In the case of Peceol®, a concentration > 50 mg/mL was achieved with all studied batches, resulting in
an increase in venetoclax concentration of 3.5- to 67.9-fold in the supersaturated state. Interestingly,
for Peceol®, the supersaturated concentration of venetoclax was maintained in the formulation for in
excess of 2 weeks.
The consecutive heating cycles were designed to investigate whether further thermal exposure
would increase venetoclax concentrations in the excipients. In the case of Peceol®, venetoclax
concentrations increased, while in the case of Capmul MCM®, an increase was observed in only
one case (batch 1), with the other batches showing a similar venetoclax concentration throughout
the heating cycles. Interestingly, in the case of triglycerides, venetoclax concentration decreased in
some cases upon each heating cycle. The initial supersaturated Captex® 1000 showed a decrease in
the amount of venetoclax with each further heating cycle for batch 1 and 2. A similar decrease was
observed for batch 3 in olive oil with the second heating cycle.
As a result of these initial screening trials, a Peceol® sLBF was used for further in vitro and
in vivo evaluation due to the high and maintained concentrations of drug in the vehicle over 2 weeks.
The drug amount in the formulation was fixed at 50 mg/mL, which was below the maximum achievable
concentration in Peceol® (batch 1: 68.3 mg/mL, batch 2: 178.62 mg/mL, and batch 3: 52.4 mg/mL).
Batch 1 was chosen for further studies, based on displaying the lowest fold increase in supersaturation
at 50 mg/mL (i.e., 2.5-fold) and hence a lower risk of precipitation relative to batch 2 (17.5-fold) and
batch 3 (11.6-fold). The sLBF was produced using two heating cycles rather than three to reduce
the thermal exposure to drug and excipient. Short-term storage studies with sLBFs produced under
these conditions confirmed that the concentration of venetoclax in the Peceol® sLBF (batch 1) was
maintained at 50 mg/mL for up to 20 days with no macroscopic signs of instability.
3.5. Drug Solubilisation during In Vitro Dispersionand Digestion
In order to study how digestion affects the supersaturated formulation, sLBF (50 mg/mL venetoclax
supersaturated in Peceol®, 5% w/v) was assessed using the dynamic in vitro lipolysis model and
compared to a Peceol® suspension (50 mg/mL venetoclax mixed in Peceol®, 5% w/v) and an aqueous
suspension (5% w/v). Initially, lipid formulations were dispersed in biorelevant buffer representing the
fasted state for 10 min prior to initiation of the digestion by the addition of porcine pancreatic lipase.
The recovery of venetoclax in the aqueous phase, lipid phase and solid phase during dispersion and
digestion is shown in Figure 4.
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Figure 4. In vitro lipolysis of venetoclax formulated as an aqueous suspension (5% w/v) (•), a Peceol®
suspension (5% w/v) (), and a supersaturated Peceol® solution (sLBF) (5% w/v) (N). (A): % of venetoclax
in the aqueous phase. Statistical significance is compared to Peceol® and the aqueous suspension. (B):
Distribution of venetoclax into the different phases after 60 min of lipolysis. (C): % of venetoclax in
the solid phase. (D): % of the venetoclax in the lipid phase. All experiments were run with n = 3 and
results are shown as the mean ± S . Statistical diff rence is indicate as ***, wher p ≤ 0.001.
The amount of venetoclax recovered in the aqueous phase is shown in Figure 4A. Upon dispersion
and after 60 min of digestion, the highest venetoclax concentration in the aqueous phase was observed
for sLBF. However, upon initiation of digestion, the sLBF showed a decrea e in venetoclax concentration
in the aqueous ph se, which correlated well with the slow i crease in the solid phase (Figure 4C). From
30 min of dig stion onwards, the netoclax concentration n the aqueou phase for sLBF start d to
increase from 0.4 ± 0.1% to 2.6 ± 0.3% of the add d venetoclax dose, hich was significantly different
60 m n after initiation of digestion to all other formulations (p < 0.05). The time delay of 30 min to
increase the ven toclax concen ration in the aqueous phase suggested that digestion of the sLBF may be
a key ontributor to the high concentration of venetoclax at the end of th in vitr lipolysis. Additionally
to the aqueous phase, for sLBF, a drug-rich aqu ous phas was present after ultrace trifugation during
digestion (Figure 5). In the case of the aqueous suspension, upon dispersion a lower venetoclax
concentration was observed n the aqueous phase when compared to sLBF. Interestingly, pon initiation
of digestion an approximate y 3-fold increase in ve etoclax c centration in the aqueous phase was
observ d f r the aqueous suspension. This concentration of 0.9 ± 0.1% was maintain d thr ghout
digestion. The overall lowes concentration was observed for the Peceol® suspension throughout
dispersion and digestion, which resulted in 0.5 ± 0.2% of the v netoclax dose solubilised after 60 min
of digestion.
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Figure 5. In vitro lipolysis sample of sLBF after ultracentrifugation. Four phases were present: lipid
phase, aqueous phase, solid phase (not shown) and drug-rich aqueous phase.
The amount of venetoclax in the lipid hase for sLBF was significantly higher compared to the
amount of venetoclax in the solid an queo s phase (p < 0.05), as presented in Figure 4D. The lipid
phase contains mainly undigested or partially digested Peceol®, which contains mainly monoglycerides
(44.9%), di l i ( 1.9 ) and triglycerides (9.3%). In the employed in vitro lipolysis, 23.5 ± 0.9% of
Peceol® wa digested after 60 min of digestion (according to equation 1 and 2). On average, 99.2 ± 0.2%
of the ve etoclax dose resided within the lipid phase during dispersion. The venetoclax dose in the
lipid phas was considered absorbable, the drug can partition into the aqu ous ph se, be absorbed
through the li id absorption pathway and be released by digestion of the lipid phas . The lipi phase
of the sLBF emonstrated only an 8% decrease in ven toclax concentratio over 60 min of digestion
in the lipolysis experiment. I the cas of the Pec ol® su pension, th venetoclax amount in the
lipid phase was igh r during dispersion com ared to the olid and aqueous hase. The amount
of venetoclax decreased from 66.5 ± 7.3% upon dispersion to 8.3 ± 2.3% during digestion, which
correlated with the amount r covered in t e solid phase (Figure 4C). This indicat d that the venetoclax
crystals in the Peceol® suspension were trapped in the lipid excipi nt, an observation which was
similar to that previously demonstrated for lipid nilotinib suspensions [25]. Overall, a comparison
between the formulati suggested that the sLBF had the ability to maintain higher conc ntrations in
the lipid and aqueous ph se relative to the suspensi s, and hence m y offer benefits in vivo.
Ven toclax recovery in the s lid phase i presented in Figure 4C. The drug particles recovered
in the solid phase need to undergo dissolution prior to absorption [27]. Hig amounts indicate that
the formulation performance in vivo might be hampered by the o r dissolution and solubility of
venetoclax in the aqueous media. The lowest amount of solid was recovered for the sLBF throughout
dispersion and digestion. D ring ispersion, no solid phase was present. After initiation of digestion,
drug precipitation occurred with up to approx. 9% f the theoretical dose recover d in the solid phase.
Thus, the amount of drug that needed to undergo redissolution was the lowest for the sLBF suggesting
a promising formulation perf rmance in vivo. The high st amount of drug in the s lid phase was
recovered in the case of the aqueous suspension. Above 98% was recov red throughout dispersion
and digestion in the soli phas , which was 11-fold higher compared to sLBF at the end of igestion.
Upon dispersion, 33.3 ± 7.3% of t e theoretical venetoclax dose was recovered in the s lid phase for
the Peceol® suspension, which further increased to 89.4 ± 4.1% upon initiation of digestion, which
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was 10-fold higher compared to the sLBF. These results indicated that the suspended particles in the
Peceol® suspension were residing/entrapped in the lipid vehicle.
3.6. In Vivo Bioavailability of Venetoclax
The in vivo performance of venetoclax was evaluated in male landrace pigs. Each pig was
administered 100 mg venetoclax as either a Peceol® sLBF (50 mg/mL, 5% w/v)), Peceol® suspension
(5% w/v) or as a pure powder in a capsule. Absolute bioavailability was calculated using in-house data.
The absolute bioavailability and the plasma concentration-time profiles are shown in Figures 6 and 7,
respectively, and the pharmacokinetic parameters in Table 6.
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Figure 6. Absolute bioavailability (Fabs) of 100 mg venetoclax as a venetoclax powder capsule, a Peceol®
suspension, and a supersaturated Peceol® solution (sLBF) in male landrace pigs. All data is presented
as the mean ± SD, where n = 3 (except for sLBF, where n = 2). Statistical difference is indicated as *,
where p ≤ 0.05.
All lipid formulations showed a higher bioavailability when compared to the venetoclax powder
capsule. The highest exposure was observed for sLBF with a relative bioavailability of 429.5 ± 151.1%
compared to the venetoclax powder (Table 6, Figure 6). While there was a trend towards a higher
exposure of sLBF compared to the Peceol® suspension, sLBF was only significantly different from the
venetoclax powder (p < 0.05). These results indicated that the formulation success depended on the
lipid excipient and the solubilisation of the drug in the sLBF.
Table 6. Pharmacokinetic parameters of oral administration of 100 mg/pig venetoclax in male landrace
pigs. Venetoclax was administered as a powder capsule, a Peceol® suspension, and a supersaturated
Peceol® solution (sLBF) (n = 3, except sLBF, where n = 2). tmax and MRT are given as median (range),
all other parameters as the mean ± SD.
Pharmacokinetic Parameter Powder Capsule Peceol® Suspension sLBF
cmax [ng/mL] 162.67 ± 99.24 355.17 ± 205.40 1032.52 ± 165.03
tmax [h] (range) 12 (10–12) 8 (7–9) 5 (4–6)
AUC 0 h–inf. [µg* h/mL] 2.00 ± 0.89 3.59 ± 1.35 7.59 ± 2.40
MRT [h] (range) 14.46 (13.67–15.53) 11.90 (10.21–12.43) 8.77 (7.13–10.41)
MAT 10.58 (9.79–11.65) 8.02 (6.33–8.55) 4.89 (3.25–6.53)
Frel [%] 1 100.00 233.24 ± 183.80 429.46 ± 151.06
Fabs [%] 4.56 ± 2.03 8.19 ± 3.08 17.35 ± 5.48
1 Relative to the powder capsule.
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The in vivo study also demonstrated a faster absorption of venetoclax from sLBF. Relative to the
powder capsule, sLBF demonstrated a statistically significant shorter time to reach the maximum plasma
concentration (tmax), mean residence time (MRT) and mean absorption time (MAT). Approximately
6 h shorter residence and absorption times were observed for the sLBF in comparison to the powder
capsule. Relative to the Peceol® suspension, sLBF showed a trend towards a quicker absorption
and shorter MRT and tmax. While this trend was not statistically significant, it indicated that the
fast absorption, and hence less risk of precipitation, may be a factor in explaining the improved
bioavailability for sLBF.Pharmaceutics 2020, 12, x FOR PEER REVIEW 15 of 21 
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w/v) (N). (A–C): Individual plasma concentration versus time profile . (D): Mean plasma concentration
versus time profiles.
4. Discussion
LBFs represent a formulation approach for enhancing oral absorption of poorly water-soluble
drugs [28] through biopharmaceutical benefits such as avoidance of a dissolution step and improved
solubilisation in vivo upon dispersion and digestion of the formulation [4]. Further advantages may
come from improved intestinal permeability and promotion of lymphatic transport. Many of these
benefits have been demonstrated for highly lipophilic grease ball drugs, which are able to form a LBF
solution. However, the drive of discovery technologies and methodologies such as high-throughput
screening, the addition of lipophilic substituents during lead optimisation or the shift in therapeutic
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target identification increasingly produces more hydrophobic as well as lipophilic candidates with a
trend of increased molecular weight [1]. A consequence of these particular hydrophobic drugs is an
overall lower aqueous and lipid solubility, which may come with lower permeability due to molecular
bulkiness and, therefore, the applicability of the classical LBF solutions is limited. As a consequence,
strategies such as lipophilic salts/ionic liquids [9,10,29], supersaturated lipid solutions [11–13,15,17] or
hybrid systems [30,31] were proposed that focus on increasing the drug load in LBFs. Nevertheless,
it remains unclear whether LBFs offer biopharmaceutical benefits to enhance the bioavailability of
these beyond Rule-of-Five drugs which display high lipophilicity and molecular weight as well as
moderate hydrophobicity.
Thermally induced supersaturation of venetoclax was observed in all lipid vehicles,
with concentrations increasing between 26% and 6690% over the experimentally determined apparent
solubility at 37 ◦C. In effect, heating the drug in lipid excipients, therefore, potentially increases
drug loadings in lipid vehicles between 126% and 6790%. The % increases in drug loading in lipids
observed for venetoclax were higher compared to typical dose loadings reported for other drugs in
sLBFs [11,12,15,17]. For example, in the case of halofantrine [12] and fenofibrate [15], dose loading
increased to 150% compared to solubility at 37 ◦C, whereas for simvastatin [11] and R4040 [17], dose
loading was increased to 200% compared to solubility at 37 ◦C. This indicates that many model drugs
already show a reasonably high solubility in the lipid vehicles or a lower therapeutic dose compared to
venetoclax. In fact, the choice of lipid vehicle is important, as indicated by the better ability to obtain
and maintain higher supersaturated venetoclax concentrations in monoglycerides when compared
to triglycerides. While venetoclax displayed an ability to supersaturate in all lipid vehicles, the final
choice of lipid vehicle will be influenced by factors such as the overall required dose loading and the
stability of the formulation over time. In our study, appropriate short-term stability was observed
for the Peceol® sLBF, where the concentration was maintained above the target of 50 mg/mL over a
2 week observational period with no macroscopic signs of instability.
In the in vivo study, the highest absolute oral bioavailability was observed for sLBF, with
17.4% ± 5.5%. sLBF showed a 2.1-fold increased bioavailability relative to the Peceol® suspension and
a 3.8-fold increase when compared to the venetoclax powder capsule, which in the latter case was
statistically significantly different (p < 0.05). Additionally, sLBF showed a faster absorption and shorter
residence time in pigs. The results from the in vivo study were in line with observations from the
in vitro lipolysis of sLBF, which suggested the combined effect of maintaining the drug within the
absorbable lipid phase and the increased venetoclax concentration observed in the aqueous digestive
phase. In a previous study with fenofibrate in minipigs, a sLBF with 150% drug load (compared to
equilibrium solubility) was compared to a LBF suspension with the same drug load (100% dissolved
and 50% suspended) [15]. The bioavailability and peak plasma concentrations of both sLBF and LBF
suspension was similar [15]. In a separate study, the drug R3040 was studied as a sLBF with 200% drug
load and a LBF suspension with the same drug load (100% dissolved and 100% suspended) in rats [17].
A similar bioavailability was observed for both formulations, while the peak plasma concentration
tended to be higher in the case of the sLBF [17]. The results of the present study with the more atypical
molecular characteristics and the higher degree of supersaturation of venetoclax, therefore, extended
the range of application of the supersaturated formulation approach in lipid vehicles.
The in vitro lipolysis showed a higher venetoclax concentration in the aqueous phase for the sLBF
compared to a Peceol® suspension and aqueous suspension after 60 min of digestion. After 60 min,
venetoclax concentrations of 20.4± 1.2 µg/mL in fasted state-simulating digestion buffer were measured.
This was in the range of the previously reported amorphous solubility of venetoclax under simulated
intestinal fluid conditions in the fasted state of approximately 21–34 µg/mL depending on the pH [20].
Therefore, venetoclax concentrations near the maximum reported aqueous concentrations were reached
with the developed sLBF. Such high venetoclax concentrations in this study agree with previous reports,
which have shown that venetoclax can achieve high supersaturation in aqueous media [20]. In addition,
venetoclax is a class III glass former (Figure 2, Figure S2, Table 1) with a high glass-forming ability,
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suggesting a reasonable stable supersaturated concentration [32]. Interestingly, in our study, a distinctly
yellow ‘fourth’ phase, presumed to be a venetoclax-rich phase, was evident after ultracentrifugation
at the bottom of the centrifugation tube (Figure 5). Given that previous studies have reported that
concentrations above the amorphous solubility lead to a glass–liquid phase separation (GLPS) [20],
this fourth phase after centrifugation may potentially represent a venetoclax-rich phase that has
formed from high drug concentrations achieved during digestion in the aqueous phase. While this
drug-rich phase is observed under non-sink conditions after ultracentrifugation, the likely impact of
such elevated concentrations in vivo is to drive the absorptive flux which is especially important for
BCS class IV drugs such as venetoclax.
In addition, the lowest amount of solid was recovered throughout dispersion and digestion for
sLBF. In fact, despite the increased kinetic stress due to dispersion and digestion, most venetoclax was
recovered in the lipid phase for sLBF, which maintained drug supersaturation throughout the 60 min.
While in previous studies supersaturated drug concentrations in in vitro lipolysis media have been
reported [11], such high concentrations of drug within the lipid phase during digestion of a sLBF have
not been reported previously for a sLBF. The high venetoclax concentration in the lipid phase may be
attributed to the relatively low digestibility of Peceol® (23.5 ± 0.9%) in the in vitro lipolysis experiment.
For highly lipophilic drugs such as venetoclax, the presence of an undigested/partially dispersed lipid
reservoir in vitro is likely to lead to an overall lower drug concentration within the aqueous digest phase.
However, in the in vivo situation, such a lipid phase may be critical to maintain bio-enhancing effects
by sustaining the aqueous phase concentration as venetoclax partitions from the lipid into the aqueous
phase. An adjustment of the in vitro model to species-specific parameters such as enzyme activity,
gastrointestinal volumes [33] and the addition of a gastric step [34,35] and an absorptive sink [36,37]
may have offered additional insights into reliably correlating in vitro formulation characteristics with
in vivo performance.
The developed supersaturation protocol in the present study was an efficient method to
supersaturate lipid vehicles within 30–60 min including heating and cooling. Previously published
supersaturation protocols required ultrasonification, a heating period of approximately 3–5 h at 60 ◦C
as well as cooling overnight at 37 ◦C [11,12,15]. Therefore, previous reports to induce supersaturation
in lipids involved processing between 13 and 15 h [11,12,15]. The newly proposed protocol employed
in this study therefore represents a more streamlined approach to increase dose loading in LBFs,
which can be readily applied in a pre-clinical drug development setting, especially for instable ad hoc
prepared formulations.
While this study demonstrated a proof of concept for a novel sLBF approach to enhance in vivo
exposure, the study was not without limitations. Firstly, it was not possible to complete a full 3 × 3
way cross-over in the in vivo study due to a failure in dosing one of the experimental units the sLBF
formulation. However, at an individual level and overall, the higher bioavailability of the sLBF was
significant. In addition, while the solubility in biorelevant media was consistent, we have also reported
venetoclax-specific variability in the estimate of venetoclax solubility in lipid excipients. It was not
readily apparent why venetoclax showed the variable results. Nonetheless, it is an important point
to note, as in early stages of drug development, variability (especially between batches) is likely to
be a major consideration given relatively limited experience with the drug. Finally, we acknowledge
that the findings presented herein are more suited to a pre-clinical environment, where a focus on
maximising exposure for safety assessment is a key priority. The approach outlined allows increasing
dose loading in lipid excipients without any needed advanced processing which is normally involved
for a technological approach that routinely requires a large amount of drug substance to produce
formulations with an appropriate short-term stability. Clearly more work is required to explore
long-term stability as well as the possible improvement of supersaturation stability considering
the incorporation of stability and performance-enhancing excipients such as polymeric stabilisers
(precipitation inhibitors) to support stabilisation of the supersaturated state in the formulation and
upon dispersion and digestion.
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5. Conclusions
The present study investigated the potential of a sLBF approach to increase the oral bioavailability
of the poorly water- and lipid-soluble compound venetoclax. A rapid and efficient supersaturation
protocol was developed and sLBFs were successfully created, leading to increased dose loadings of
between 1.2-fold and 67.9-fold. A higher degree of supersaturation was observed in monoglycerides
compared to triglycerides. While the supersaturated concentrations were high, a therapeutically
relevant dose was only achieved in the long chain monoglyceride Peceol®. A Peceol® sLBF was a
viable approach for dosing beyond Rule-of-Five drugs in a pre-clinical setting, leading to an increased
in vivo exposure of approximately 4-fold compared to a venetoclax powder capsule. Compared to
the corresponding LBF suspension, an approximately 2-fold increase was demonstrated for sLBF. The
in vitro lipolysis provided a mechanistic basis for explaining the sLBF performance relative to a control
LBF and aqueous suspension in terms of higher solubility in the aqueous digest phase and the ability
to maintain supersaturated drug concentrations in the lipid phase even after 60 min of digestion.
Consequently, the present study demonstrated that a sLBF approach is a viable approach to increase
the bioavailability of high-molecular-weight, hydrophobic and/or lipophilic beyond Rule-of-Five
drugs. The findings of this study are of particular relevance to pre-clinical development, where an
sLBF approach offers advantages relative to alternative bio-enabling approaches in terms of ease of
preparation of high-dose-load formulations with the potential to maximise in vivo exposure.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/6/564/s1,
Figure S1: DSC of venetoclax batches. Given are the melting temperatures and enthalpy of fusion (mean ± SD;
n = 3). Figure S2: Hot-stage microscopy of venetoclax batch 1 under cross-polarised light. Pictures were taken at
various temperatures during heating from room temperature to 165 ◦C (10 ◦C/min) and during cooling to 25 ◦C
(20 ◦C/min).
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